Resistance to Targeted Therapies in Multiple Myeloma | Silvia Ling | Springer
This volume provides an overview of targeted therapies in Multiple Myeloma, disease biology, strategies to overcome resistance, and future developments….
This volume provides an overview of targeted therapies in Multiple Myeloma, disease biology, strategies to overcome resistance, and future developments….
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction…
Large granular lymphocytic (LGL) leukemia is a lymphoproliferative disorder characterized by persistent clonal expansion of mature T- or natural killer cells in the blood via…
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Current Hematologic Malignancy Reports – Summarize best practices for management of patients with early myelofibrosis (MF). Myelofibrosis is a progressive myeloproliferative neoplasm (MPN) that…
Current Hematologic Malignancy Reports – Acute lymphoblastic leukemia (ALL) is a widely heterogeneous disease in terms of genomic alterations, treatment options, and prognosis. While ALL…
A remarkably high rate of post-transplant relapse in patients with TP53-mutated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) calls to question the utility of allogeneic stem cell…
Following positive response data from the phase III PhALLCON study, ponatinib plus chemotherapy receives accelerated U.S. FDA approval for the treatment of adult patients with…
This early analysis suggests that the combination of oral decitabine plus cedazuridine with venetoclax for higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia is safe in most…
The following ESMO Clinical Practice Guideline (CPG) has been recently updated with new treatment recommendations: